住院肝硬化患者静脉血栓栓塞症预防的血栓预防:国际血栓与止血学会科学标准化委员会指南
该指南由国际血栓与止血学会科学标准化委员会制定,针对住院肝硬化患者医院相关静脉血栓栓塞症(HA-VTE)的预防。指南建议将门静脉血栓作为未来研究的独立临床重要终点,推荐不将血小板减少和/或凝血酶原时间/国际标准化比值延长作为抗凝血栓预防的绝对禁忌证,建议按当地方案进行抗凝血栓预防,并建议低分子肝素或磺达肝癸钠优于普通肝素;肾功能不全时建议低分子肝素优于普通肝素;危重患者建议个体化考虑血栓预防。
要点
- 建议将门静脉血栓作为未来研究的独立临床重要终点。
- 推荐不将血小板减少和/或凝血酶原时间/国际标准化比值延长作为抗凝血栓预防的绝对禁忌证。
- 建议按当地方案进行抗凝血栓预防,建议低分子肝素或磺达肝癸钠优于普通肝素。
核心结论
- 住院肝硬化患者存在HA-VTE风险且与死亡率增加相关,需在血栓与出血风险间权衡。
- 指南建议将门静脉血栓作为未来研究的独立临床重要终点。
- 推荐不将血小板减少和/或凝血酶原时间/国际标准化比值延长作为抗凝血栓预防的绝对禁忌证。
- 建议按当地方案进行抗凝血栓预防,并建议低分子肝素或磺达肝癸钠优于普通肝素。
- 肾功能不全时建议低分子肝素优于普通肝素;危重患者建议个体化考虑血栓预防。
研究设计与样本
- 该文件为国际血栓与止血学会科学标准化委员会发布的指南文件,基于对住院肝硬化患者HA-VTE发生率、危险因素及血栓预防证据的综述制定。
主要发现
- 住院肝硬化患者HA-VTE发生率和危险因素数据有限,因关键研究的严格入选和排除标准。
- 肝硬化患者止血功能紊乱常被视为抗凝血栓预防的禁忌证,但证据不支持将血小板减少和/或凝血酶原时间/国际标准化比值延长作为绝对禁忌证。
关键数值与推荐
- 建议将门静脉血栓作为未来研究的独立临床重要终点。
- 推荐不将血小板减少和/或凝血酶原时间/国际标准化比值延长作为抗凝血栓预防的绝对禁忌证。
- 建议按当地方案进行抗凝血栓预防,建议低分子肝素或磺达肝癸钠优于普通肝素。
- 肾功能不全时建议低分子肝素优于普通肝素。
- 危重患者建议个体化考虑血栓预防。
临床怎么用
- 住院肝硬化患者应按当地方案进行抗凝血栓预防,优先选择低分子肝素或磺达肝癸钠而非普通肝素。
- 肾功能不全的住院肝硬化患者建议使用低分子肝素而非普通肝素。
- 危重住院肝硬化患者建议个体化考虑血栓预防。
局限性
- 因关键VTE风险评估和血栓预防研究的严格入选和排除标准,指导该患者群体决策的数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hospital-associated venous thromboembolism (HA-VTE) is a major cause of morbidity and mortality and is internationally recognized as a significant patient safety issue. While cirrhosis was traditionally considered to predispose to bleeding, these patients are also at an increased risk of VTE, with an associated increase in mortality. Hospitalization rates of patients with cirrhosis are increasing, and decisions regarding thromboprophylaxis are complex due to the uncertain balance between thrombosis and bleeding risk. This is further accentuated by derangements of hemostasis in patients with cirrhosis that are often considered contraindications to pharmacological thromboprophylaxis. Due to the strict inclusion and exclusion criteria of seminal studies of VTE risk assessment and thromboprophylaxis, there is limited data to guide decision making in this patient group. This guidance document reviews the incidence and risk factors for HA-VTE in patients with cirrhosis, outlines evidence to inform the use of thromboprophylaxis, and provides pragmatic recommendations on VTE prevention for hospitalized patients with cirrhosis. In brief, in hospitalized patients with cirrhosis: We suggest inclusion of portal vein thrombosis as a distinct clinically important endpoint for future studies. We recommend against the use of thrombocytopenia and/or prolongation of prothrombin time/international normalized ratio as absolute contraindications to anticoagulant thromboprophylaxis. We suggest anticoagulant thromboprophylaxis in line with local protocols and suggest low molecular weight heparin (LMWH) or fondaparinux over unfractionated heparin (UFH). In renal impairment, we suggest LMWH over UFH. For critically ill patients, we suggest case-by-case consideration of thromboprophylaxis. We recommend research to refine VTE risk stratification, and to establish the optimal dosing and duration of thromboprophylaxis.
引用
- Roberts LN, Hernandez-Gea V, Magnusson M, et al. Thromboprophylaxis for venous thromboembolism prevention in hospitalized patients with cirrhosis: Guidance from the SSC of the ISTH. J Thromb Haemost. 2022. PMID: 35948998. doi:10.1111/jth.15829
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。